Skip to content
    Clinical Trials

    SUNRAY-02 Phase III Trial: Olomorasib Plus Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC

    Chaft et alFuture Oncology

    SUNRAY-02 Phase III Trial: Olomorasib Plus Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC
    More than half of patients diagnosed with early-stage non-small cell lung cancer (NSCLC) experience disease recurrence following definitive therapy. While targeted therapeutic approaches have established significant, clinically meaningful outcomes in early-stage disease harboring EGFR, ALK, or RET alterations, no targeted agents are currently approved for early-stage KRAS G12C-mutant NSCLC.
    Olomorasib is a potent, highly selective next-generation KRAS G12C inhibitor that has shown antitumor and intracranial activity alongside a manageable safety profile in patients with KRAS G12C-mutant metastatic NSCLC. Preclinical evaluations demonstrate that KRAS G12C inhibition can reverse KRAS-mediated immune suppression to generate an inflamed tumor microenvironment receptive to immune checkpoint inhibition, establishing a mechanistic rationale for combined targeted therapy and immunotherapy.
    The global, placebo-controlled phase III SUNRAY-02 study is evaluating this approach across two cohorts of patients with stage II–III KRAS G12C-mutant NSCLC following definitive management. In Part A, patients with completely resected NSCLC receive olomorasib or placebo combined with pembrolizumab. In Part B, patients with unresectable stage II–III disease receive olomorasib or placebo in combination with durvalumab. Across both cohorts, combination therapy is administered for approximately 1 year, followed by olomorasib or placebo monotherapy to complete up to 3 years of total treatment.

    Key Takeaways

    • Olomorasib has demonstrated antitumor and intracranial activity with a manageable safety profile in KRAS G12C-mutant metastatic NSCLC, accompanied by preclinical evidence showing KRAS G12C inhibition reverses tumor-mediated immune suppression.